Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vicore Pharma Holding ABVCRE +4.17%13 3-Year Book Growth Rate is 4.20% as of Jun. 2026. GuruFocus rates VCRE with a GF Score™ of 13/100. The stock has 2 warning signs investors should review. Among 1,132 Biotechnology companies, Vicore Pharma Holding AB ranks better than 69.79% on this metric.
During the past 12 months, Vicore Pharma Holding AB's average Book Value per Share Growth Rate was -21.70% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 4.20% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -5.60% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 0.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Vicore Pharma Holding AB was 41.90% per year. The lowest was -18.00% per year. And the median was -5.45% per year.
Vicore Pharma Holding AB (NAS:VCRE) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Vicore Pharma Holding AB 3-Year Book Growth Rate Related Terms
VCRE vs VRTX, REGN, RVMD: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Vicore Pharma Holding AB's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vicore Pharma Holding AB 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Vicore Pharma Holding AB's 3-Year Book Growth Rate falls into.
Vicore Pharma Holding AB 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 4.20% mean?
Vicore Pharma Holding AB (VCRE) has a 3-Year Book Growth Rate of 4.20% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Vicore Pharma Holding AB and its competitors. According to the industry distribution chart, Vicore Pharma Holding AB ranks #342 out of 1132 companies in the Biotechnology industry, placing it in the top 30.2%.
Is Vicore Pharma Holding AB's 3-Year Book Growth Rate too high?
Vicore Pharma Holding AB's current 3-Year Book Growth Rate is 4.20%. Based on the distribution chart, Vicore Pharma Holding AB ranks #342 out of 1132 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vicore Pharma Holding AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's 3-Year Book Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vicore Pharma Holding AB ranks #342 out of 1132 companies for 3-Year Book Growth Rate. This puts Vicore Pharma Holding AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Vicore Pharma Holding AB and its competitors. Vicore Pharma Holding AB's current 3-Year Book Growth Rate is 4.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (VCRE) has a current 3-Year Book Growth Rate of 4.20%. The current 3-Year Book Growth Rate is 4.20%. Vicore Pharma Holding AB's overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Vicore Pharma Holding AB (VCRE), the current 3-Year Book Growth Rate is 4.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score
Get the complete analysis for VCRE
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VCRE has been successfully added to your 
